Fluvoxamine as a Treatment for COVID-19 - Frankly Speaking Ep 265

<p>Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: <a href='https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-265'>https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-265</a></p> <p>Overview: Most cases of COVID-19 will resolve without interventions, but some patients are at high risk for complications. Several treatment options for high-risk patients are now available to help prevent the need for hospitalization. Join us to review a recent large, randomized trial evaluating fluvoxamine as a treatment for high-risk patients who were diagnosed with COVID-19.   Episode resource links:</p> <ul><li>Reis G, et al. TOGETHER investigators. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022 Jan;10(1):e42-e51</li> <li>Berwanger O. Fluvoxamine for outpatients with COVID-19: where do we stand? Lancet Glob Health. 2022 Jan;10(1):e2-e3. doi: 10.1016/S2214-109X(21)00501-5</li> <li><a href='https://activ6study.org/'>https://activ6study.org/</a></li> </ul> <p>Guest: Alan M. Ehrlich, MD, FAAFP   Music Credit: Richard Onorato</p>